Neurogene Inc.
Close on Oct 19, 2026
- Market cap
- $545.08M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 18, 2024 | After market close | – | $-1.19 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 18, 2024 | After market close | – | – | – |
Press releases
Announcements Neurogene filed with the SEC
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
EVERY BREAKTHROUGH BEGINS WITH BELIEF August 2026 Corporate Presentation
Results of operations · EX-99.2 to Form 8-K
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Restarting Development in Rett Syndrome NGN-401 for Rett Syndrome Phase 1/2 Update June 29, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
EVERY BREAKTHROUGH BEGINS WITH BELIEF June 2026 Corporate Presentation
Regulation FD disclosure · EX-99.2 to Form 8-K
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
EVERY BREAKTHROUGH BEGINS WITH BELIEF May 2026 Corporate Presentation
Results of operations · EX-99.2 to Form 8-K
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
EVERY BREAKTHROUGH BEGINS WITH BELIEF March 2026 Corporate Presentation
Results of operations · EX-99.2 to Form 8-K
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
EVERY BREAKTHROUGH BEGINS WITH BELIEF January 2026 Corporate Presentation
Regulation FD disclosure · EX-99.2 to Form 8-K
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
Every Breakthrough BEGINS WITH BELIEF r r t r BE I S IT BELIEF Corporate Presentation November 2025
Results of operations · EX-99.2 to Form 8-K
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
Every Breakthrough BEGINS WITH BELIEF r r t r BE I S IT BELIEF NGN-401 Phase 1/2 Interim Data Update November 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Neurogene Announces First Participant Dosed in Embolden ™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Regulation FD disclosure · EX-99.2 to Form 8-K
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Regulation FD disclosure · EX-99.2 to Form 8-K
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Results of operations · EX-99.2 to Form 8-K
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Regulation FD disclosure · EX-99.2 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Other events · EX-99.1 to Form 8-K
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Results of operations · EX-99.2 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Regulation FD disclosure · EX-99.1 to Form 8-K
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
CONFIDENTIAL Interim Clinical Data from Phase 1/2 Trial Evaluating NGN-401 Gene Therapy for the Treatment of Rett Syndrome November 11, 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Neurogene Announces Oversubscribed $200 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Results of operations · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT transgene regulation technology
Results of operations · EX-99.2 to Form 8-K
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
NGN-401 for Rett Syndrome Leveraging EXACT gene regulation technology
Regulation FD disclosure · EX-99.1 to Form 8-K